ABCELLERA BIOLOGICS (8QQ) - Net Assets
Based on the latest financial reports, ABCELLERA BIOLOGICS (8QQ) has net assets worth €966.90 Million EUR (≈ $1.13 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.36 Billion ≈ $1.59 Billion USD) and total liabilities (€390.05 Million ≈ $456.00 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ABCELLERA BIOLOGICS tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €966.90 Million |
| % of Total Assets | 71.26% |
| Annual Growth Rate | -1.47% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 12.16 |
ABCELLERA BIOLOGICS - Net Assets Trend (2021–2025)
This chart illustrates how ABCELLERA BIOLOGICS's net assets have evolved over time, based on quarterly financial data. See 8QQ days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for ABCELLERA BIOLOGICS (2021–2025)
The table below shows the annual net assets of ABCELLERA BIOLOGICS from 2021 to 2025. For live valuation and market cap data, see ABCELLERA BIOLOGICS (8QQ) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €966.90 Million ≈ $1.13 Billion |
-8.44% |
| 2024-12-31 | €1.06 Billion ≈ $1.23 Billion |
-8.35% |
| 2023-12-31 | €1.15 Billion ≈ $1.35 Billion |
-6.56% |
| 2022-12-31 | €1.23 Billion ≈ $1.44 Billion |
+20.23% |
| 2021-12-31 | €1.03 Billion ≈ $1.20 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ABCELLERA BIOLOGICS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 111.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €996.39 Million | 103.05% |
| Total Equity | €966.90 Million | 100.00% |
ABCELLERA BIOLOGICS Competitors by Market Cap
The table below lists competitors of ABCELLERA BIOLOGICS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Songyuan Automotive Safety
SHE:300893
|
$1.27 Billion |
|
Carabao Group Public Company Limited
BK:CBG
|
$1.27 Billion |
|
Alphatec Holdings Inc
NASDAQ:ATEC
|
$1.27 Billion |
|
Cairn Homes PLC
IR:C5H
|
$1.27 Billion |
|
Shanghai Tofflon Science Tech
SHE:300171
|
$1.27 Billion |
|
Alphamin Resources Corp.
JSE:APH
|
$1.27 Billion |
|
PT Sarana Menara
JK:TOWR
|
$1.27 Billion |
|
Cofco Biochemical Anhui Co Ltd
SHE:000930
|
$1.27 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ABCELLERA BIOLOGICS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,056,084,000 to 966,904,000, a change of -89,180,000 (-8.4%).
- Net loss of 146,412,000 reduced equity.
- Other factors increased equity by 57,232,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-146.41 Million | -15.14% |
| Other Changes | €57.23 Million | +5.92% |
| Total Change | €- | -8.44% |
Book Value vs Market Value Analysis
This analysis compares ABCELLERA BIOLOGICS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.48x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.31x to 1.48x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.62 | €4.76 | x |
| 2022-12-31 | €4.30 | €4.76 | x |
| 2023-12-31 | €3.96 | €4.76 | x |
| 2024-12-31 | €3.57 | €4.76 | x |
| 2025-12-31 | €3.22 | €4.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ABCELLERA BIOLOGICS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -194.88%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.40x
- Recent ROE (-15.14%) is below the historical average (-3.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 14.96% | 40.90% | 0.28x | 1.29x | €50.89 Million |
| 2022 | 12.85% | 32.66% | 0.32x | 1.25x | €35.19 Million |
| 2023 | -12.70% | -385.00% | 0.03x | 1.29x | €-261.63 Million |
| 2024 | -15.42% | -564.83% | 0.02x | 1.29x | €-268.47 Million |
| 2025 | -15.14% | -194.88% | 0.06x | 1.40x | €-243.10 Million |
Industry Comparison
This section compares ABCELLERA BIOLOGICS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,525,237,982
- Average return on equity (ROE) among peers: -60.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ABCELLERA BIOLOGICS (8QQ) | €966.90 Million | 14.96% | 0.40x | $1.27 Billion |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $243.06 Million | -74.97% | 0.23x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $242.58 Million | -85.63% | 0.52x | $173.06 Million |
| PreveCeutical Medical Inc (18H) | $-5.78 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.58 Million | -6.53% | 0.28x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $1.82 Billion |
| BioNTech SE (22UA) | $20.25 Billion | 4.60% | 0.14x | $20.05 Billion |
About ABCELLERA BIOLOGICS
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more